当前位置: X-MOL 学术Pharmacol. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hope on the Horizon: Promising Therapies for Steatotic Liver Disease
Pharmacological Reviews ( IF 19.3 ) Pub Date : 2024-07-01 , DOI: 10.1124/pharmrev.124.001269
Amirhossein Sahebkar 1 , Ali H Eid 2
Affiliation  

Steatotic liver disease (SLD) is a highly prevalent chronic liver disease with significant challenges for global health. The pathophysiology of SLD involves an interplay among genetic, endocrine, and metabolic factors. Successful management of SLD entails accurate diagnosis and disease monitoring through noninvasive methods such as advanced imaging techniques and biomarkers. Many emerging pharmacotherapies for SLD are now in the pipeline, which target different pathways like collagen turnover, fibrogenesis, inflammation, and metabolism. The recent approval of resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) has been a milestone in addressing the unmet medical need for an efficacious SLD treatment. Finally, the potential of personalized medicine approaches and interdisciplinary cooperation in improving patient outcomes and reducing disease burden should be strongly pursued.

中文翻译:


希望就在眼前:脂肪肝疾病的有希望的治疗方法



脂肪肝病(SLD)是一种高度流行的慢性肝病,对全球健康构成重大挑战。 SLD 的病理生理学涉及遗传、内分泌和代谢因素之间的相互作用。 SLD 的成功管理需要通过先进成像技术和生物标志物等非侵入性方法进行准确诊断和疾病监测。许多针对 SLD 的新兴药物疗法目前正在研发中,它们针对不同的途径,如胶原蛋白周转、纤维形成、炎症和代谢。最近批准瑞美罗治疗非肝硬化代谢功能障碍相关脂肪性肝炎 (MASH),这是解决有效 SLD 治疗未得到满足的医疗需求的一个里程碑。最后,应大力探索个性化医疗方法和跨学科合作在改善患者治疗结果和减轻疾病负担方面的潜力。
更新日期:2024-06-14
down
wechat
bug